BTG2-DT: A Potential Drug Target and Biomarker (G730227)

Target Name: BTG2-DT

NCBI ID: G730227

BTG2-DT

Other Name(s): BTG2 divergent transcript, transcript variant 2 | BTG2-DT variant 2 | BTG2 divergent transcript | LINC01136

BTG2-DT: A Potential Drug Target and Biomarker

BTG2-DT, also known as BTG2-Divergent Transcript, is a gene that encodes a protein known as BTG2, which is a key regulator of cell growth and differentiation. The BTG2 gene has four splice variants, each of which produces a different isoform of the BTG2 protein.

One of the splice variants, BTG2-DT, has been shown to be a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The BTG2-DT gene is located on chromosome 18q21 and has been implicated in the development and progression of several diseases, including cancer. Studies have shown that individuals with certain genetic variations in the BTG2 gene are at an increased risk of developing these diseases.

One of the key features of the BTG2-DT gene is its ability to cause a split in the DNA double helix, a process known as exon skipping. This allows for the production of a truncated BTG2 protein that is missing the N-terminus, as well as the C-terminus, of the original BTG2 protein.

The absence of the N-terminus and C-terminus of the BTG2 protein has been shown to disrupt its normal function, leading to a variety of negative effects on cell growth and differentiation. This is thought to contribute to the pathogenesis of many diseases, including cancer and neurodegenerative diseases.

In addition to its role in disease, the BTG2-DT gene has also been shown to be a potential biomarker for several diseases. For example, studies have shown that individuals with certain genetic variations in the BTG2 gene are at an increased risk of developing Alzheimer's disease, a neurodegenerative disorder.

Furthermore, the BTG2-DT gene has also been shown to be involved in the regulation of cellular processes that are critical for normal development and growth, such as cell division, migration, and angiogenesis. This suggests that BTG2-DT may be a useful target for drugs that are aimed at modulating these processes, potentially leading to therapeutic benefits for a variety of diseases.

In conclusion, BTG2-DT is a gene that has been shown to be involved in the development and progression of a variety of diseases, including cancer and neurodegenerative disorders. Its ability to cause exon skipping and its potential as a drug target make it an attractive target for researchers and clinicians who are working to develop new treatments for these diseases. Further research is needed to fully understand the role of BTG2-DT in disease and to develop effective therapies based on its properties.

Protein Name: BTG2 Divergent Transcript

The "BTG2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTG2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets